Good morning, myeloma world.

As we were finalizing today's edition of Myeloma Morning, we were suddenly reminded of how inter­na­tional the field of multiple myeloma research truly is.

The first research study we review below is by a team of German researchers. We also discuss two studies by Korean researchers, and a topic sparked by a report written by Chinese researchers. At the end of today's report, the list of new myeloma research articles also in­cludes publications by investigators in India, Israel, Italy, and the United States.

As we …

Good morning, myeloma world.

There are times when we write an edition of Myeloma Morning, and it turns out completely different than expected. Today's edition is a perfect example.

As we were planning today's report, we thought it would focus on two preclinical research studies examining the potential new myeloma therapies CCF642 and BDA-366.

And, yes, we do start today's report with summaries of those two studies.

But readers will be making a mistake if they stop after reading that section of today's article. Because the third study we …

Good morning, myeloma world.

We've got a lot of new myeloma-related research to cover today, so we'll get right down to business.

The first two studies we will review are related to autologous (own) stem cell transplantation.

One study looks at whether myeloma cells make their way into the infusion of a patient's own stem cells that a patient gets during the autologous transplant process. The study finds that, in some cases, myeloma cells do make it into the stem cell infusion, and when this happens, it could – again, could – …

Good morning, myeloma world.

It's been a very chilly morning here at Myeloma Morning Headquarters. After teasing us with summerlike temperatures the past few weeks, Mother Nature has decided she's not done with the part of the thermometer below freezing.

We'll be focusing on two new research studies in today's report.

The first study looks at outcomes of allogeneic (donor) stem cell trans­plan­ta­tion for multiple myeloma. Using outcomes from a single U.S. treatment center, the study authors find that whether or not an allo­geneic trans­plant patient had high-risk disease at diagnosis did …

Good morning, myeloma world.

It's just Tuesday, and already the week is getting in­ter­est­ing. We'll be reporting on just two myeloma-related news items today, but one of them is the kind of news we don't see here at Myeloma Morning very often.

In particular, the German bio­tech com­pany MorphoSys has sued Janssen Biotech and Genmab, the two com­pa­nies that have devel­oped and mar­keted Darzalex (dara­tu­mu­mab). MorphoSys contends that sales of Darzalex infringe on a MorphoSys patent.

In addi­tion, we report on a study that came out last …

Good morning, myeloma world.

It truly was a dark and stormy night when we sat down early yesterday to start writing the next edition of Myeloma Morning. A spring windstorm was howling about outside and, before we knew it, the wily gusts had conspired to knock out electricity at Myeloma Morning Headquarters.

Fortunately, the watts and volts are back in working order, and we're glad to be writing for you again.

All the news we cover in today's Myeloma Morning concerns recently published research studies.

One study by …

Good morning, myeloma world.

After a busy week here at Myeloma Morning Headquarters, we're pleased to report that things are a bit more relaxed today. We're not sure if it's the weekend, or the cooler, overcast weather outside. Whatever the reason, we're enjoying the somewhat slower pace.

That pace is reflected in what we'll be covering in today's edition of Myeloma Morning. We'll be discussing just three new myeloma research articles.

The first article is a discussion of how to treat relapsed multiple myeloma, co-authored by Dr. Pieter Sonneveld, a leading myeloma …